Update on the phase IV confirmatory study of Aduhelm for Alzheimer’s disease – Biogen + Eisai

Biogen Inc. and Eisai Co., Ltd. provided an important update on the continuing progress of the Phase IV post-marketing confirmatory study of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use in Alzheimer’s disease. The companies anticipate submitting the final protocol for review to the FDA in March 2022, with the initiation of patient screening in May 2022. The study is […]

Neuroprotective mechanism altered by Alzheimer’s disease risk genes

The brain has a natural protective mechanism against Alzheimer’s disease, and researchers at Baylor College of Medicine, Texas Children’s Hospital and collaborating institutions have discovered that gene variants associated with risk of developing the disease disturb the protective mechanism in ways that can lead to neurodegeneration. The researchers also showed in a fruit fly model of the condition that a […]

Scientists discover potential cause of Alzheimer’s Disease

Existing drugs may offer effective treatment. Prevailing theories posit plaques in the brain cause Alzheimer’s disease. New UC Riverside research points to cells’ slowing ability to clean themselves as the likely cause of unhealthy brain buildup. Along with signs of dementia, doctors make a definitive Alzheimer’s diagnosis if they find a combination of two things in the brain: amyloid plaques […]